Esthesioneuroblastoma natural history, complications and prognosis: Difference between revisions
Simrat Sarai (talk | contribs) No edit summary |
Simrat Sarai (talk | contribs) No edit summary |
||
| Line 9: | Line 9: | ||
Most studies have found a correlation between Hyams grade and prognosis [13,17,21,23]. In a meta-analysis that included five studies in which lesions were graded histologically, the mean five-year survival was 56 percent for those with low-grade lesions (Hyams I and II) versus 20 percent for those with high-grade lesions (Hyams III and IV) [23]. However, a SEER study of 281 patients treated from 1973 to 2010 showed that patients with grade I and II tumors had a 10-year overall survival rate of 67 percent and those with high grade tumors (III and IV) had a 10-year overall survival rate of 34 percent. For high-grade tumors, multivariate analysis showed Kadish stage predicted for worse disease-specific survival and radiation independently predicted for improved disease-specific survival (B-Tajudden). | Most studies have found a correlation between Hyams grade and prognosis [13,17,21,23]. In a meta-analysis that included five studies in which lesions were graded histologically, the mean five-year survival was 56 percent for those with low-grade lesions (Hyams I and II) versus 20 percent for those with high-grade lesions (Hyams III and IV) [23]. However, a SEER study of 281 patients treated from 1973 to 2010 showed that patients with grade I and II tumors had a 10-year overall survival rate of 67 percent and those with high grade tumors (III and IV) had a 10-year overall survival rate of 34 percent. For high-grade tumors, multivariate analysis showed Kadish stage predicted for worse disease-specific survival and radiation independently predicted for improved disease-specific survival (B-Tajudden). | ||
Treatment usually involves combined chemotherapy and/or radiotherapy with surgical excision. Prognosis is significantly affected by presence of distant metastases. | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center | |||
|valign=top| | |||
|+ | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Metastasis}} | |||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Five-year survival}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
:No distant metastases | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*60% | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
:Distant metastases | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*0% | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
:Small localised tumors | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*85-90% | |||
|- | |||
|} | |||
no distant metastases: 60% 5-year survival 6 | |||
distant metastases: 0% 5-year survival | |||
Small localised tumours have a high cure rate, up to 85-90% | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 18:54, 14 January 2016
|
Esthesioneuroblastoma Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Esthesioneuroblastoma natural history, complications and prognosis On the Web | |
|
American Roentgen Ray Society Images of Esthesioneuroblastoma natural history, complications and prognosis | |
|
FDA on Esthesioneuroblastoma natural history, complications and prognosis | |
|
CDC on Esthesioneuroblastoma natural history, complications and prognosis | |
|
Esthesioneuroblastoma natural history, complications and prognosis in the news | |
|
Blogs on Esthesioneuroblastoma natural history, complications and prognosis | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]
Overview
Natural History
Clinical presentation is usually secondary to nasal stuffiness and rhinorrhoea or epistaxis. Presentation is often delayed and symptoms may have been present for many months. Patients often present late with larger tumours which can extend into the intracranial compartment (25-30% at diagnosis) and usually result in anosmia.
Complications
Prognosis
Most studies have found a correlation between Hyams grade and prognosis [13,17,21,23]. In a meta-analysis that included five studies in which lesions were graded histologically, the mean five-year survival was 56 percent for those with low-grade lesions (Hyams I and II) versus 20 percent for those with high-grade lesions (Hyams III and IV) [23]. However, a SEER study of 281 patients treated from 1973 to 2010 showed that patients with grade I and II tumors had a 10-year overall survival rate of 67 percent and those with high grade tumors (III and IV) had a 10-year overall survival rate of 34 percent. For high-grade tumors, multivariate analysis showed Kadish stage predicted for worse disease-specific survival and radiation independently predicted for improved disease-specific survival (B-Tajudden).
Treatment usually involves combined chemotherapy and/or radiotherapy with surgical excision. Prognosis is significantly affected by presence of distant metastases.
| Metastasis | Five-year survival |
|---|---|
|
|
|
|
|
|
no distant metastases: 60% 5-year survival 6 distant metastases: 0% 5-year survival Small localised tumours have a high cure rate, up to 85-90%